22.418 articles found

IDENTIFICATION AND USE OF GPRC VARIANTS IN THE TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE

KOTRAIAH VINAYAKA, KONG DEHE, PANDO MATTHEW PAUL.

· 2007-06-28

IDENTIFICATION AND USE OF GPRC VARIANTS IN THE TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE

KOTRAIAH VINAYAKA, KONG DEHE, PANDO MATTHEW PAUL.

· 2007-06-28

IDENTIFICATION AND USE OF GPRC VARIANTS IN THE TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE

KOTRAIAH VINAYAKA, KONG DEHE, PANDO MATTHEW PAUL.

· 2007-06-28

Identification and use of GPRC variants in the treatment and diagnosis of parkinson's disease

VINAYAKA KOTRAIAH, DEHE KONG, PAUL PANDO MATTHEW.

· 2007-06-28

IDENTIFICATION AND USE OF GPRC VARIANTS IN THE TREATMENT ANDDIAGNOSIS OF PARKINSON'S DISEASE

KONG DEHE, KOTRAIAH VINAYAKA, PANDO MATTHEW PAUL.

· 2007-06-28

Identification and use of GPRC variants in the treatment and diagnosis of parkinson's disease

PANDO MATTHEW PAUL, KONG DEHE, KOTRAIAH VINAYAKA.

· 2007-06-28

Novel therapeutic strategies for the treatment of protein-misfolding diseases.

Rochet JC.

Expert Rev Mol Med · 2007-06-28

DOI: 10.1017/s1462399407000385PMID: 17597554

Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment.

Antonelli T, Fuxe K, Tomasini MC, Mazzoni E, Agnati LF, Tanganelli S, Ferraro L.

Prog Neurobiol · 2007-06-28

DOI: 10.1016/j.pneurobio.2007.06.006PMID: 17673354

Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease.

Karamanakos PN, Pappas P, Marselos M.

Pharm World Sci · 2007-06-28

DOI: 10.1007/s11096-007-9138-7PMID: 17597418

Patterns of levodopa response in Parkinson's disease: a clinico-pathological study.

Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ.

Brain · 2007-06-24

DOI: 10.1093/brain/awm142PMID: 17586867

Dosage forms for movement disorder treatment

NANGIA AVINASH, JACOB JULES, YEH JAMES, MOSLEMY PEYMAN, VERMA DAYA D, HASWANI DINESH K, SHAKED ZE'EV.

· 2007-06-22

N-(4-{ 2-[4-aryl-piperazin-1-yl]ethyl} cyclohexyl)-acetamide derivatives for the treatment of neuropsychiatric disorders

DANVY DENIS, LEVOIN NICOLAS, CAPET MARC, BERREBI-BERTRAND ISABELLE, CALMELS THIERRY, ROBERT PHILIPPE, LECOMTE JEANNE-MARIE, SCHWARTZ JEAN-CHARLES, LIGNEAU XAVIER.

· 2007-06-21